Cargando…
IL-6–targeted therapies to block the cytokine or its receptor drive distinct alterations in T cell function
Therapeutics that inhibit IL-6 at different points in its signaling pathway are in clinical use, yet whether the immunological effects of these interventions differ based on their molecular target is unknown. We performed short-term interventions in individuals with type 1 diabetes using anti–IL-6 (...
Autores principales: | Speake, Cate, Habib, Tania, Lambert, Katharina, Hundhausen, Christian, Lord, Sandra, Dufort, Matthew J., Skinner, Samuel O., Hu, Alex, Kinsman, MacKenzie, Jones, Britta E., Maerz, Megan D., Tatum, Megan, Hocking, Anne M., Nepom, Gerald T., Greenbaum, Carla J., Buckner, Jane H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Clinical Investigation
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746808/ https://www.ncbi.nlm.nih.gov/pubmed/36282595 http://dx.doi.org/10.1172/jci.insight.159436 |
Ejemplares similares
-
IL-6-Driven pSTAT1 Response Is Linked to T Cell Features Implicated in Early Immune Dysregulation
por: Lambert, Katharina, et al.
Publicado: (2022) -
A standardized metric to enhance clinical trial design and outcome interpretation in type 1 diabetes
por: Ylescupidez, Alyssa, et al.
Publicado: (2023) -
Early Prognostic Indicators of Subsequent Hospitalization in Patients with Mild COVID-19
por: Ylescupidez, Alyssa, et al.
Publicado: (2021) -
Uncovering Pathways to Personalized Therapies in Type 1 Diabetes
por: Linsley, Peter S., et al.
Publicado: (2021) -
Response to Comment on So et al. Autoantibody Reversion: Changing Risk Categories in Multiple-Autoantibody–Positive Individuals. Diabetes Care 2020;43:913–917
por: So, Michelle, et al.
Publicado: (2020)